Connect Biopharma Holdings Limited
NASDAQ: CNTB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Barry D. Quart
- Employees
- 62
- Headquarters
- Taicang, China
- IPO year
- 2021
- Market cap
- $133.5M
- Website
- https://www.connectbiopharm.com
Loading CNTB…
Loading profile data…Frequently asked questions about CNTB
What does Connect Biopharma Holdings Limited (CNTB) do?
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha...
Where does CNTB trade?
Connect Biopharma Holdings Limited (CNTB) trades on the NASDAQ Global Market.
What sector is CNTB in?
Connect Biopharma Holdings Limited (CNTB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Connect Biopharma Holdings Limited?
Barry D. Quart is the chief executive officer of Connect Biopharma Holdings Limited (CNTB).
Where is Connect Biopharma Holdings Limited headquartered?
Connect Biopharma Holdings Limited is headquartered in China.
Does CNTB pay a dividend?
Connect Biopharma Holdings Limited (CNTB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CNTB go public?
Connect Biopharma Holdings Limited (CNTB) completed its initial public offering in 2021.
Is CNTB an ADR?
Yes — CNTB is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Connect Biopharma Holdings Limited reporting and dividends follow the underlying issuer.